Live Breaking News & Updates on Egfr Mutant

Stay updated with breaking news from Egfr mutant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Sabari on the Potential Role for Patritumab Deruxtecan in NSCLC

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer. ....

Department Of Medicine , Grossman School Of Medicine , Langone Health Perlmutter Cancer Center , York University , New York University , Grossman School , Perlmutter Cancer Center , Lung Cancer , Non Small Cell Lung Cancer , Patritumab Deruxtecan , Egfr Mutant ,

COMING SOON: Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib

Martin Dietrich, MD, PhD, provides a look at an upcoming program exploring key data from the phase 3 MARIPOSA-2 study in patients with EGFR-mutated advanced NSCLC. ....

Without Lazertinib , Rapid Readouts , Lung Cancer , Non Small Cell Lung Cancer , Egfr Mutant , Mariposa 2 ,

COMING SOON: Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

Expert oncologist Alex Spira, MD, PhD, FACP, shares his excitement for an upcoming program centered on the MARIPOSA study in advanced NSCLC following the ESMO 2023 annual meeting. ....

Lazertinib Versus Osimertinib , Mutated Advanced , Primary Results From , Non Small Cell Lung Cancer , Advanced Nsclc , Metastatic Nsclc , Mariposa Trial , Mariposa Study , Egfr Mutated , Egfr Mutant , Combination Therapy , Novel Therapy , Egfr Tki , Tyrosine Kinase Inhibitors , Met Inhibitor , Chrysalis Study , Chrysalis Trial , Exon 20 , Egfr L858r , Efficacy Data , Overall Survival , Progression Free Survival , Pfs Data , Cns Disease , Brain Metastases , Safety Data ,

Dr Jänne on the FLAURA2 and MARIPOSA Trials of Single-Agent Osimertinib in EGFR-Mutant NSCLC

Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.

....

Lowe Center , Chen Huang Center , Harvard Medical School , Dana Farber Cancer Institute , Belfer Center , Thoracic Oncology , Applied Cancer Science , Lung Cancers , Lung Cancer , Dana Farber , Egfr Mutant ,